Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Zafirlukast discontinued

The manufacturer of zafirlukast (Accolate®) has discontinued this product with effect from the end of March 2018. No further supplies are being made and it is predicted that minimal supplies will be available within the supply chain.

Commercial reasons are cited for this decision and it is stressed that there were no safety concerns with this medicine. Zafirlukast is a leukotriene receptor antagonist and as such the closest available alternative is montelukast.

Action: Clinicians should be aware of this product being discontinued. It would be prudent to run clinical system searches to identify any patients who are currently prescribed this product to allow a review and arrangements made to identify a suitable alternative.

Share 'Zafirlukast discontinued' on Email Share 'Zafirlukast discontinued' on Delicious Share 'Zafirlukast discontinued' on Digg Share 'Zafirlukast discontinued' on Facebook Share 'Zafirlukast discontinued' on Google+ Share 'Zafirlukast discontinued' on reddit Share 'Zafirlukast discontinued' on StumbleUpon Share 'Zafirlukast discontinued' on Twitter

atomic-wealth

No Comments to “Zafirlukast discontinued”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,953 spam comments.

atomic-wealth
fond-illness
summer